ES2960392T3 - Agente terapéutico contra el cáncer - Google Patents

Agente terapéutico contra el cáncer Download PDF

Info

Publication number
ES2960392T3
ES2960392T3 ES18894766T ES18894766T ES2960392T3 ES 2960392 T3 ES2960392 T3 ES 2960392T3 ES 18894766 T ES18894766 T ES 18894766T ES 18894766 T ES18894766 T ES 18894766T ES 2960392 T3 ES2960392 T3 ES 2960392T3
Authority
ES
Spain
Prior art keywords
cancer
acceptable salt
pharmacologically acceptable
amino
phenylbenzoxazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES18894766T
Other languages
English (en)
Spanish (es)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
J Pharma Co Ltd
Original Assignee
J Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by J Pharma Co Ltd filed Critical J Pharma Co Ltd
Application granted granted Critical
Publication of ES2960392T3 publication Critical patent/ES2960392T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)
ES18894766T 2017-12-28 2018-08-01 Agente terapéutico contra el cáncer Active ES2960392T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017253385 2017-12-28
PCT/JP2018/028887 WO2019130637A1 (ja) 2017-12-28 2018-08-01 がん治療薬

Publications (1)

Publication Number Publication Date
ES2960392T3 true ES2960392T3 (es) 2024-03-04

Family

ID=67066788

Family Applications (1)

Application Number Title Priority Date Filing Date
ES18894766T Active ES2960392T3 (es) 2017-12-28 2018-08-01 Agente terapéutico contra el cáncer

Country Status (10)

Country Link
US (1) US12458628B2 (enExample)
EP (1) EP3733175B1 (enExample)
JP (4) JP6546367B1 (enExample)
KR (1) KR102377742B1 (enExample)
CN (1) CN111491632A (enExample)
BR (1) BR112020012766A2 (enExample)
CA (1) CA3083343C (enExample)
ES (1) ES2960392T3 (enExample)
MX (1) MX2020006678A (enExample)
WO (1) WO2019130637A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110945361B (zh) * 2017-11-07 2024-01-09 J制药股份有限公司 抗pd-1/pd-l1抗体疗法显效性的预测和提高方法以及评价癌症恶性程度的方法
EP3968785A4 (en) 2019-05-14 2023-01-11 Tyme, Inc. COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER
CN112336859A (zh) * 2019-08-06 2021-02-09 上海绿谷制药有限公司 通过抑制t细胞摄取氨基酸治疗阿尔茨海默病的方法
CN115515575A (zh) * 2020-01-17 2022-12-23 迪美公司 用于调节癌症的酪氨酸衍生物
US10905698B1 (en) 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections
JPWO2022102687A1 (enExample) * 2020-11-11 2022-05-19
KR20250145578A (ko) 2023-01-16 2025-10-13 제이 파마 가부시끼가이샤 담도암 치료제

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008081537A1 (ja) * 2006-12-28 2008-07-10 Human Cell Systems, Inc. Ｌａｔ１阻害活性を有する芳香族アミノ酸誘導体、それを含有するｌａｔ１阻害活性剤及びその製造方法
WO2015173970A1 (ja) * 2014-05-15 2015-11-19 ジェイファーマ株式会社 抗悪性腫瘍剤組成物
JP2017155023A (ja) 2016-03-04 2017-09-07 ジェイファーマ株式会社 Ｌａｔ１阻害活性を有する芳香族アミノ酸誘導体を含有する注射剤
CN110945361B (zh) 2017-11-07 2024-01-09 J制药股份有限公司 抗pd-1/pd-l1抗体疗法显效性的预测和提高方法以及评价癌症恶性程度的方法
WO2021040043A1 (ja) 2019-08-30 2021-03-04 ジェイファーマ株式会社 特定の遺伝子マーカーを有する患者に用いる医薬組成物
JPWO2022102687A1 (enExample) 2020-11-11 2022-05-19

Also Published As

Publication number Publication date
JP2020073586A (ja) 2020-05-14
JP2019151672A (ja) 2019-09-12
WO2019130637A1 (ja) 2019-07-04
JPWO2019130637A1 (ja) 2019-12-26
EP3733175A1 (en) 2020-11-04
KR20200101960A (ko) 2020-08-28
US12458628B2 (en) 2025-11-04
EP3733175B1 (en) 2023-10-04
KR102377742B1 (ko) 2022-03-22
EP3733175A4 (en) 2021-08-18
BR112020012766A2 (pt) 2020-12-01
MX2020006678A (es) 2020-08-31
CA3083343A1 (en) 2019-07-04
JP6546367B1 (ja) 2019-07-17
US20200405695A1 (en) 2020-12-31
JP6734971B2 (ja) 2020-08-05
CN111491632A (zh) 2020-08-04
JP2023101705A (ja) 2023-07-21
CA3083343C (en) 2022-04-26
JP7541400B2 (ja) 2024-08-28

Similar Documents

Publication Publication Date Title
US12458628B2 (en) Cancer therapeutic
ES2424476T3 (es) Nanopartículas cargadas con fármaco antitumoral quimioterápico
ES2525257T3 (es) Composiciones de ciclopolisacárido y de bendamustina
EP3400072B1 (en) Formulations for treating bladder cancer
JP7466822B2 (ja) 亜鉛－γ－ＰＧＡ組成物およびがんを処置するための方法
CN111356445B (zh) 包含培美曲塞的口服用药学组合物及其制备方法
CN109475554A (zh) 基于脂核苷酸的ards治疗
US11141421B2 (en) Antitumor agent for biliary tract cancer and method for treating biliary tract cancer
TW202421112A (zh) （－）－表沒食子兒茶素沒食子酸酯類化合物的應用
CN104688676B (zh) 穿心莲内酯浓缩型液体组方及其医药用途
CN104688669A (zh) 人参皂苷浓缩型液体组方及其医药用途
CN115400115B (zh) 多西他赛白蛋白组合物和免疫检查点抑制剂的组合及用途
CN117440810A (zh) 抗肿瘤剂
CN115192721B (zh) 一种膀胱灌注药物复方制剂及其制备方法和应用
US20060264388A1 (en) Method for treating liver cancer by intrahepatic administration of nemorubicin
CN111939165A (zh) 非天然人参皂苷3β-O-Glc-DM治疗脑瘤的用途
WO2019164010A1 (ja) 膀胱がん用抗腫瘍剤および膀胱がんの処置方法
CN104771371B (zh) 4-(3,5-二甲氧苯基)-5-(3-羟基-4-甲氧基苯基)咪唑制剂
US8273721B2 (en) Combination treatment for bladder cancer
CN102429914A (zh) 具有抗肿瘤作用的复方制剂